Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo and ArQule announced a flurry of activity surrounding their oncology collaboration, including regulatory and clinical updates for c-Met inhibitor ARQ 197 and expansion of their drug discovery program based on ArQule kinase inhibitor platform (AKIP) technology
You may also be interested in...
Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals
Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals